The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
versant launches pep2tango to develop innovative multi-target obesity drug
Versant Ventures has launched Pep2Tango Therapeutics, aiming to create a groundbreaking obesity drug that combines four treatment mechanisms: GLP-1, GIP, amylin, and calcitonin receptors. The startup claims its approach could lead to greater efficacy and reduced muscle loss compared to existing therapies. With significant market potential, Pep2Tango's innovative strategy reflects a shift towards multi-target solutions in obesity treatment.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.